{{medical}}
{{Drugbox
| IUPAC_name = (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
| image = Fluticasone_furoate.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|fluticasone-furoate}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = C(鼻腔內吸入用)
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 鼻腔內

<!--Pharmacokinetic data-->
| bioavailability = 0.51% (鼻腔內)
| protein_bound = 91%
| metabolism = 鼻腔內<br>[[肝臟|肝臟]]([[CYP3A4|CYP3A4]]-中介)
| elimination_half-life = 10小時
| excretion = [[腎臟|腎臟]]

<!--Identifiers-->
| CAS_number = 80474-14-2
| ATC_prefix = R01
| ATC_suffix = AD12
| ATC_supplemental = 
| PubChem = 5311101
 | DrugBank = DB00588
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JS86977WNV
| ChEBI = 74899
| ChEMBL = 1676

<!--Chemical data-->
| C=27 | H=29 | F=3 | O=6 | S=1 
| molecular_weight = 538.576 g/mol
| smiles = FCSC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C) [C@@]3(F)[C@@H](O)C[C@]12C
}}

'''糠酸氟替卡松'''({{lang|en|Fluticasone furoate}}、氟替卡松糠酸酯、氟替卡松莫米松、合成的三氟化皮質類固醇)為源自[[氟替卡松|氟替卡松]]的一種人工合成[[皮質類固醇|皮質類固醇]]，為治療過敏性[[鼻炎|鼻炎]]用。

==上市商標名==
美國[[葛蘭素史克|葛蘭素史克]]藥廠定商標名為<'''Veramyst'''>上市；而澳大利亞、加拿大、歐盟、南非、台灣、墨西哥、及以色列等國定商標名為<'''Avamys'''>(艾敏釋)上市。

在印度<Cipla>公司定商標名為<'''Furamist'''>上市。 而在印度亦由<Reddys>博士以商標名為<'''Ennhale'''>上市。<ref name="pmid19571596">{{cite journal |author=Bruni FM, De Luca G, Venturoli V, Boner AL |title=Intranasal corticosteroids and adrenal suppression |journal=Neuroimmunomodulation |volume=16 |issue=5 |pages=353–62 |year=2009 |pmid=19571596 |doi=10.1159/000216193 |url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000216193 |access-date=2013-10-31 |archive-date=2011-11-22 |archive-url=https://web.archive.org/web/20111122075010/http://content.karger.com/produktedb/produkte.asp?typ=fulltext |dead-url=no }}</ref>

==藥品容具及使用法==
藥品容具以「鼻用噴液(霧)懸浮劑({{lang|en|Nasal Spray Suspension}})」的結構設計。溫度須保持在[[攝氏|攝氏]]30°以下。<ref name="pmid19571596"/>

==延伸性組合藥劑==
另種延伸性的[[組合藥劑|組合藥劑]](combination drug)[[糠酸氟替卡松/維蘭特羅|糠酸氟替卡松/維蘭特羅]](fluticasone furoate/vilanterol)已由[[美国食品药品监督管理局|美国食品药品监督管理局]]批准在美國使用。「糠酸氟替卡松/維蘭特羅」主要為[[慢性阻塞性肺病|慢性阻塞性肺病]]({{lang|en|COPD}})所產生的「氣流阻塞」病理現象之長期護理治療用，亦使用在"慢性[[支气管炎|支气管炎]]"和"[[肺氣腫|肺氣腫]]"等之患者的治療上。<ref>{{cite web | url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm351664.htm | title = FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease | publisher = [[Food_and_Drug_Administration|Food and Drug Administration]] | date = May 10, 2013 | accessdate = 2013-10-31 | archive-date = 2017-01-18 | archive-url = https://web.archive.org/web/20170118091240/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm351664.htm | dead-url = no }}</ref>

==參見==
* [[氟替卡松|氟替卡松]]
*[[丙酸氟替卡松|丙酸氟替卡松]]({{tsl|en|Fluticasone propionate|Fluticasone propionate}}/氟替卡松丙酸酯)
* [[糖皮质激素#药理作用|糖皮质激素抗炎作用]]

==參考文獻==
{{Reflist}}
{{-}}
{{Corticosteroids}}
{{Glucocorticoids}}
{{GlaxoSmithKline}}

[[Category:糖皮质激素|Category:糖皮质激素]]
[[Category:糠酸酯|Category:糠酸酯]]
[[Category:有机氟化合物|Category:有机氟化合物]]